Revance Therapeutics reported $-74376000 in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Adamas Pharmaceuticals ADMS:US -19518000 7.17M
Aerie Pharmaceuticals AERI:US $ -33.31M 2.2M
Antares Pharma ATRS:US $ 7.22M 1.66M
Bristol Myers Squibb BMY:US $ 5289M 67M
Cara Therapeutics CARA:US $ -1013000 29.73M
Coherus Biosciences CHRS:US $ -38.53M 11.22M
Eli Lilly And LLY:US $ 1470.5M 518.1M
Endo International Ordinary Shares ENDP:US $ 220.65M 39.03M
Flexion Therapeutics FLXN:US $ -30312000 8.1M
Johnson & Johnson JNJ:US $ 8058M 282M
Neurocrine Biosciences NBIX:US $ 30.5M 27M
Procter & Gamble PG:US $ 5035M 1471M
Revance Therapeutics RVNC:US $ -74.38M 2.18M
Supernus Pharmaceuticals SUPN:US $ 28.96M 2.28M
Teva Pharmaceutical Industries TEVA:US $ 807M 13M
Zogenix ZGNX:US $ -58M 0.89M